Russell Parker, MD
Obstetrics · Norman, OKNPI 1205844420
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,177 of the $4,380 with a category attached, or 72.5%. 35 manufacturers reported payments, led by Intuitive Surgical at 30.2% of the total. Reporting peaked in 2019 at $1,415 and has fallen 58.4% since, to $589 in 2025.
Across 167 payments — averaging $26.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- AbbVie$801
- Mayne Pharma Commercial LLC$296
- Pfizer$170
- Exeltis, USA Inc.$143
- Astellas Pharma US Inc$133
- plus $2K from 29 others
What the payments were for
- Travel & lodging$45310%
- Food & beverage$3,17773%
- Education$75017%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $1,323 |
| AbbVie(2 entities) | 37 | $801 |
| Mayne Pharma Commercial LLC | 16 | $296 |
| Pfizer | 9 | $170 |
| Exeltis, USA Inc. | 8 | $143 |
| Astellas Pharma US Inc | 7 | $133 |
| Sumitomo Pharma America, Inc. | 5 | $114 |
| Organon | 8 | $107 |
| Sage Therapeutics, LLC | 6 | $92 |
| Daiichi Sankyo Inc. | 4 | $91 |
| Aspira Women's Health Inc | 1 | $89 |
| Millicent US Inc | 5 | $85 |
| Hologic Sales And Service, LLC | 4 | $80 |
| Amgen | 4 | $79 |
| Exact Sciences | 5 | $77 |
| Avion Pharmaceuticals | 4 | $69 |
| Evofem Biosciences, Inc. | 4 | $64 |
| Agile Therapeutics, Inc. | 3 | $60 |
| Meditrina | 4 | $56 |
| Dexcom, Inc. | 2 | $51 |
| Myovant Sciences Inc. | 2 | $45 |
| Therapeuticsmd, Inc. | 3 | $41 |
| Scynexis, Inc. | 2 | $35 |
| Roche Diagnostics Corporation | 2 | $33 |
| Novo Nordisk | 2 | $33 |
| Mylan Pharmaceuticals Inc. | 2 | $32 |
| Bayer | 2 | $30 |
| Johnson & Johnson | 1 | $28 |
| Minerva Surgical, Inc | 2 | $28 |
| Boston Scientific | 1 | $23 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
| Axonics, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Mission Pharmacal Company | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,110
- ORIAHNN$101
How this compares
Too few obstetrics providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 17 | $20,058 |
| PremarinEstrogens, Conjugated | 24 | $12,324 |
| Estradiol | 293 | $5,720 |
| Tolterodine Tartrate ErTolterodine Tartrate | 46 | $4,740 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 13 | $1,391 |
| Raloxifene Hcl | 28 | $1,309 |
| Clobetasol Propionate | 47 | $1,220 |
| ProgesteroneProgesterone, Micronized | 20 | $1,042 |
| Oxybutynin Chloride ErOxybutynin Chloride | 30 | $741 |
| Fluocinonide | 25 | $739 |
| LantusInsulin Glargine,hum.Rec.Anlog | 13 | $679 |
| Zolpidem Tartrate | 53 | $572 |
| Rosuvastatin Calcium | 21 | $502 |
| Medroxyprogesterone Acetate | 32 | $464 |
| Spironolactone | 16 | $423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $133 | $20,05817 claims |
| PfizerPremarin | $170 | $12,32424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obstetrics providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other obstetrics in Norman
- Alyssa OhsNorman$1K
- Sarah BradleyTulsa$9K
- Juan CornejoDuncan$5K
- Lauren ChinneryTulsa$4K
- Elisa Depani-SparkesEdmond$1K
- Robin MikelOklahoma City$1K
- Jazmin BakerTulsa$900
- Ryan GholsonOwasso$758
- Kelly KinnearOklahoma City$541
- Abby RussellOklahoma City$204
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.